Xenetic Biosciences(XBIO)

Focus: Xenetic Biosciences is a public biotech company focused on biologic drugs, novel oncology therapeutics, and vaccines. The company operates at pre-revenue scale with minimal commercial traction.

Oncology Vaccines

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Xenetic Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Xenetic Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$3M

FY2025

Pipeline & Clinical Trials

Sodium Cridanimod

Endometrial Cancer

PHASE_2

Clinical Trials (1)

NCT03077698An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Phase 2

Help build intelligence for Xenetic Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology focus with potential upside in high-value therapeutic areas if pipeline advances
Public company status provides liquidity and credibility versus private biotech
R&D-intensive mandate (132% R&D intensity) signals commitment to scientific innovation

Watch Out For

Only 1 active clinical trial (Phase 2) represents minimal pipeline depth and commercialization risk
$9M cash position (FY 2024) with consistent $4M+ annual losses raises serious runway concerns
Zero active job postings indicate potential hiring freeze or severe headcount constraints
Flat revenue ($3M) with no marketed drugs creates instability and limited career progression paths

Generated by Claude from Xenetic Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

Publications: 3 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$3M2%

R&D Spend

$3M(132%)6%

Net Income

-$4M

Research Publications(3)

Recent peer-reviewed publications with author affiliations at this company

Clinical Application of Polysialylated Deoxyribonuclease and Erythropoietin.

Recent patents on drug delivery & formulation

2018

PMID:30019653

CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

2016

PMID:27324388

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo